This is a descriptive, prospective, single centre study. This study will assess PSMA expression via the uptake of radiolabelled PSMA-ligand using PET/CT imaging in mTNBC lesions pre-identified on 18F-FDG PET/CT in order to evaluate the feasibility of molecular radionuclide therapy in refractory mTNBC using the Lutetium-177 radiolabelled PSMA.
Written informed consent in accordance with institutional guidelines and obtained prior to any study procedure
Women with ≥ 18 years-old
Eastern Cooperative Oncology Group Performance Status of 0 to 2
Confirmed diagnosis of progressive metastatic TNBC and presenting measurable disease on 18F-FDG PET/CT (performed within 2 weeks) or Brain MRI in case of progressive brain metastases (performed within 4 weeks) prior to PSMA PET/CT.
Pregnant or lactating patients
Other active neoplastic disease
Treatment by another molecule that is the object of investigation within 30 days
Skin only metastatic disease